Hematopoietic Recovery clinical trials

Explore recruiting hematopoietic recovery clinical trials.

Recruiting hematopoietic recovery studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hematopoietic Recovery trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRIT PHASE I/II STUDY

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A phase I/II multi-centre study to assess the tolerability and efficacy of the addition of hydroxyurea to standard ara-C and daunorubicin-based therapy for adults (age ≥ 18 years of age) with newly diagnosed acute myeloid leukaemia (AML)

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Netherlands, Czechia, Austria, Italy, France, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

FLAsH-IV-AML: A phase I/II multi-center study to assess the tolerability and efficacy of the addition of hydroxyurea to salvage treatment with fludarabine, ara-C, idarubicin and venetoclax for adults with relapsed or refractory acute myeloid leukemia

Sweden

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase II study of (early) combination salvage therapy with Venetoclax and intensified Decitabine in Relapsed/Refractory AML

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Netherlands, Finland, Estonia, Spain, Sweden, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hematopoietic Recovery trials by city

Hematopoietic Recovery in Toronto Hematopoietic Recovery in Vancouver Hematopoietic Recovery in Montreal Hematopoietic Recovery in Calgary Hematopoietic Recovery in Edmonton Hematopoietic Recovery in Ottawa Hematopoietic Recovery in Winnipeg Hematopoietic Recovery in Quebec City Hematopoietic Recovery in Hamilton Hematopoietic Recovery in Kitchener Hematopoietic Recovery in London Hematopoietic Recovery in Halifax Hematopoietic Recovery in New York Hematopoietic Recovery in Los Angeles Hematopoietic Recovery in Chicago Hematopoietic Recovery in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease